After completion of a number of validation shipments Maverick New Zealand has commenced ongoing production of device tissues this month against a clients need for a dual sourced supply chain to meet regulatory requirements, and board directives to manage disease risk.
Any seasonal impacts of the winter slowdown common with New Zealand slaughtering will be ably covered with Australian production produced and shipped in complete accordance with client requirements, during this period.
9th February 2012. Maverick Biomaterials was today awarded ISO 13485:2003 certified by BSI, valid to 8th February 2015.
Subsequent to a recent AQIS Audit Maverick has been granted Intermediate Products listing to the EU. Approval was granted 25th January 2012.
Maverick recently received an audit by Australian Quarantine Inspection Services (AQIS) personnel with regard to attaining listing as an exporter of "intermediate Products" to the EU. Listing is expected within the month, therefore easing constraints on exporting of...
Maverick Biomaterials Pty Ltd, producer of cross linked GBR1 bovine pericardium in Australia and New Zealand, was audited on 23rd November by BSi for ISO 13485 Certification. This certification will optimise Maverick Biomaterials production and export of cross linked...
Maverick Biomaterials is making solid progress towards probable attainment of ISO 13485 certification for Q1 2012. A Notify body audit will be completed late in the year with Mavericks Quality Manager quietly confident of a successful outcome. This will be well...
Maverick Biomaterials is continuing to advance its IP portfolio with regard to 3 Dimensional (3D) fixation of specifically sourced raw pericardium from it supplier Maverick Biosciences. Recent production for a range of global clients has been well received, with...